Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro

Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0123722. doi: 10.1128/aac.01237-22. Epub 2022 Nov 9.

Abstract

The antituberculosis candidate OPC-167832, an inhibitor of DprE1, was active against Mycobacterium abscessus. Resistance mapped to M. abscessus dprE1, suggesting target retention. OPC-167832 was bactericidal and did not antagonize activity of clinical anti-M. abscessus antibiotics. Due to its moderate potency compared to that against Mycobacterium tuberculosis, the compound lacked efficacy in a mouse model and is thus not a repurposing candidate. These results identify OPC-167832-DprE1 as a lead-target couple for a M. abscessus-specific optimization program.

Keywords: DprE1; Mycobacterium abscessus; NTM; OPC-167832; SigA; nontuberculous mycobacteria.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Mice
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Mycobacterium abscessus*
  • Mycobacterium tuberculosis*

Substances

  • Anti-Bacterial Agents